Drug Profile
Myadept- Adeptio Pharmaceuticals
Latest Information Update: 19 Nov 2018
Price :
$50
*
At a glance
- Originator Adeptio Pharmaceuticals
- Class Antirheumatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Autoimmune disorders
Most Recent Events
- 19 Nov 2018 Myadept is still in phase II trials for Autoimmune disorders in United Kingdom (Adeptio Pharmaceuticals pipeline, November 2018)
- 27 Aug 2015 Phase II clinical trial in Autoimmune disorders in United Kingdom (unspecified route)